I-Mab to develop Genexine's HyLeukin in China

Genexine Inc. (KOSDAQ:095700) granted I-Mab Biopharma (Shanghai, China) exclusive rights to develop and commercialize HyLeukin for cancer in China, Hong Kong, Macau and Taiwan. Genexine will receive an upfront payment and is eligible for milestones and tiered, single-digit royalties. Financial details were not disclosed.

HyLeukin comprises engineered IL-7 fused with IgD and IgG4 using Genexine's hyFc long-acting Fc fusion protein technology. Early next year, Genexine plans to start a Korean Phase Ib trial of HyLeukin to treat solid tumors. I-Mab did not respond in time for publication with its development plans...